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Background: Human tuberculosis is a contagious-
infectious disease mainly caused by Mycobacterium tuber-
culosis, which is an aerobic pathogenic bacterium that
establishes its infection usually in the lungs. About one
third of the world’s population is currently infected with
M. tuberculosis; 10% of those infected will develop clinical
disease, particularly those who also have the human immun-
odeﬁciency virus (HIV) infection. This problem is further
compounded by a dramatic increase in multidrug-resistant
strains of M. tuberculosis which demands the search
for alternative antimycobacterial drugs. In this effort,
diazepine derivatives, which showed a broad spectrum of
biological activity especially antitumoral is presented as
a promising source of new compounds-leaders. Using the
existing capacity that posses the Colombian National Insti-
tute of Health (NIH) for to develop reproducible in vitro tests
against mycobacteria species and the research trajectory
of Grupo de Investigación de Compuestos Heterocíclicos,
the aim of this study was to determine the activity against
15 Mycobacterium spp strains and clinical isolates of 12
diazepine derivatives.
Methods: The synthesis of pyrimidodiazepines by
microwave irradiation (200 ◦C, 300W) during 2-8minutes
of equimolar mixture of 2-R-4,5,6-triamino-pyrimidines and
chalcones in DMF (0.5mL) and catalytic amount of BF3.OEt2
(0.5mL. The minimum inhibitory concentration (MIC) was
determined by colorimetric broth microdilution method.
The activity was evaluated against ﬁve M. tuberculosis ATCC
strains, 5 isolates of Beijing genotype and 5 clinical isolates
of nontuberculous mycobacteria. Isoniazid and rifampicin
were used as control drugs.
Results: In total six diazepine derivatives showed mod-
erate activity at concentrations in a range between
16-32g/mL (Good activity CMI <10g/ mL), three were
active against 13 microorganisms; the rest just inhibited the
growth of M. tuberculosis strains.
Conclusion: Diazepine derivatives scaffolds over the
years have gained an ongoing interest for biological
activities as anticancer, anti-bacterial, psychotropics, anti-
convulsant, anti-viral, and herbicidal. This is the ﬁrst
report of antimycobacterial activity of diazepine compounds
developed entirely in Colombia, in addition, also includes
multidrug-resistant isolates classiﬁed in the national resis-
tance studies conducted in the Colombian National Institute
of Health (NIH).
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ive-year trend of antimicrobial susceptibility rates
nd daptomycin activity among Staphylococcus aureus
solates collected in Latin American medical eenters
2005-2009)
.J. biedenbach, R.N. jones, H. Sader ∗
JMI Laboratories, North Liberty, IA, USA
Background: Daptomycin is lipopeptide with a unique
echanism of action and rapid bactericidal activity against
ram-positive cocci. Daptomycin is approved for the treat-
ent of Gram-positive pathogen associated complicated
kin and skin structure infections (cSSSI) and S. aureus (SA)-
ssociated bacteremia and endocarditis and in the United
tates, Europe and some Latin American (LA) countries. The
n vitro activity of daptomycin and comparator agents was
valuated against clinical isolates of SA collected in four LA
ountries over ﬁve years.
Methods: 6,031 SA isolates were collected in 10 med-
cal centers located in Argentina (1,075), Brazil (2,637),
hile (1,345) and Mexico (974). Isolates were mainly from
loodstream (42.1%) and cSSSI (28.6%). Susceptibility (S)
as determined by the CLSI broth microdilution method
n cation-adjusted Mueller-Hinton broth supplemented to
0mg/L of calcium for daptomycin tests.
Results: The overall oxacillin resistance (MRSA) rate in LA
as 41.1% and ranged from 32.1-39.0% in Brazil and Mexico
o 51.7-51.9% in Argentina and Chile. MRSA rates increased
ontinuously from 34.7 (2005) to 48.4% (2009). Daptomycin
as highly active against SA in all LA countries with MIC50
nd MIC90 values of 0.25 and 0.5mg/ml, respectively. Over-
ll, daptomycin was highly active against MRSA (100.0%
, see table) as was vancomycin (MIC50/90, 1/1mg/ml;
00% S) and linezolid (MIC50/90, 1/2mg/ml; >99.9% S).
rythromycin resistance was higher in Chile and Mexico
46.5-54.5%) than in Argentina and Brazil (38.2-39.4%). Over-
ll constitutive clindamycin resistance was 78.8% in LA.
MP/SMX and tetracycline resistance was much higher in
razil (20.6-23.6%) compared to other countries (1.5-6.2%).
evoﬂoxacin and gentamicin resistance was highest in Chile
t 52.1% and 42.8%, respectively.
ation (no. of
SA strains)
Cumulative % inhibited at daptomycin MIC
(g/ml) of:
≤0.06 0.12 0.25 0.5 1 2
rgentina
(1,075)
0.0 2.3 62.1 98.5 100.0 -
razil (2,637) 0.1 2.1 61.1 98.4 100.0 -
hile (1,345) 0.2 2.8 57.3 97.9 100.0 -
exico (974) 0.5 3.9 74.6 99.2 99.9 -
ll regions
Methicillin- 0.2 3.3 77.3 99.1 >99.9 100.0MRSA
(2479)
0.1 1.5 41.6 97.5 100.0 -
